Fig. 3

VISTA augmented phagocytosis of cancer cells. (A) Quantification of phagocytosis with THP-1 derived M0-like macrophages induced by Rituximab (RTX, 0.1 µg/ml). (B) Quantification of phagocytosis with CD34⁺ CB cell-derived M0-like, M1-like, M2a-like, and M2c-like macrophages induced by RTX (0.1 µg/ml). n.s., not significant. ^*P < 0.05, ^**P < 0.01, and ^***P < 0.001 by one-way ANOVA with post hoc intergroup comparisons using Tukey’s test. (C) Quantification of phagocytosis with PBMC derived M0-like, M1-like, M2a-like, and M2c-like macrophages induced by RTX (0.1 µg/ml). (D) The increase in phagocytosis of PBMC derived macrophages upon RTX (0.1 µg/ml) treatment. (E) Correlation between VISTA expression on PBMC derived macrophages and basal levels of phagocytosis. Pearson’s r and linear regression p values were shown, ^*P < 0.05